iBio (IBIO)
Developing AI-enabled antibodies for obesity and body composition.
Something off on this page? Send us feedback.
Develops AI-enabled antibodies for obesity and cardiometabolic disease, advancing internally selected candidates. The portfolio includes a clinical-stage muscle-preservation program and a preclinical Activin E program, with no documented marketed product or current product-sales stream.
Develops therapeutic antibodies for obesity and cardiometabolic disease with an AI-enabled platform that combines computational target and epitope design, protein modeling, discovery and lead optimization. Its model centers on advancing internally selected candidates rather than operating only as a contract manufacturer.
IBIO-600, a long-acting anti-myostatin/GDF11 antibody, has entered a first-in-human study in adults with obesity and targets muscle preservation during weight loss. IBIO-610 is a preclinical long-acting Activin E antibody whose reported body-composition results come from obese non-human primates, including work alongside semaglutide.
No marketed therapeutic or current product-sales stream was documented in the opened record. Clinical progression, regulatory authorization, manufacturing strategy, and commercialization or partnering remain required before therapeutic sales.
Company facts
Target rangeAs of Sep 2, 2026
Latest analyst notes
| Date | Firm | Action | Target |
|---|---|---|---|
| Jun 8, 2026 | Raymond James | Target | $5 |
| Oct 17, 2025 | Leerink Partners | Target | $2 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $56.4M · Total debt $2.2M · Total assets $99.1M · Shareholders' equity $85.7M
- Revenue
- $0
- Operating income
- $0
- Net income
- −$10.6M
No dividends on record.
| Institutions52 holders · as of Mar 31, 2026 | 39.11% | 19.43M shares | |
| Insiders7 holders · as of Mar 27, 2026 | 0.61% | 304.9K shares | |
| Otherremainder | 60.28% | 29.95M shares |
49.68M company shares as of Sep 3, 2026 · institutions as of Mar 31, 2026 · holders as of their latest filing
Two share counts disagree (49.68M in the company's Sep 3, 2026 report, 15.79M elsewhere); stakes use the report.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Evidence |
|---|---|---|---|
Affinity Healthcare Fund, LPInstitution | 8.62% | 4.28M | 13Gfiled Aug 26, 2025 ↗ |
Vestal Point Capital, LPInstitution | 8.61% | 4.28M | 13Gfiled Nov 14, 2025 ↗ |
Cormorant Asset Management, LPInstitution | 7.72% | 3.83M | 13Gfiled May 15, 2026 ↗ |
Affinity Asset Advisors, LLCInstitution | 6.25% | 3.11M | 13Fas of Mar 31, 2026 |
Frazier Life Sciences Management, L.P.Institution | 3.93% | 1.95M | 13Fas of Mar 31, 2026 |
| See all 25 → | |||
13F — a manager's quarterly holdings · 13D/13G — an ownership statement filed at 5% or more
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Mar 26, 2026 | Marc Banjak | officer: Chief Legal Officer | +13,934 | $1.65 |
| Mar 19, 2026 | Martin Brenner | director, officer: See Remarks | +12,336 | $2.02 |
| Mar 19, 2026 | Felipe Duran | officer: Chief Financial Officer | +24,835 | $2.02 |
- Eli Lilly
Leading injectable body-composition adjunct in GLP-1 obesity care.
- Scholar Rock
Direct myostatin-pathway rival for preserving lean mass in obesity.
- Regeneron
Myostatin antibody program targets the same GLP-1 body-composition gap.
- Veru
Oral lean-mass-preservation adjunct in GLP-1 obesity treatment.
ComparePre-market
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| iBio | $1.32 | 0.00% | $20.7M | — | — | 206.8 | — |
| Eli Lilly | $1,167.77 | +0.72% | $1.09T | 38.9 | 28.4 | 13.7 | +47.7% |
| Scholar Rock | $56.10 | +0.38% | $6.72B | — | — | — | — |
| Regeneron | $851.82 | −0.02% | $87.78B | 21.1 | 14.1 | 5.7 | +16.7% |
| Veru | $2.75 | +0.38% | $44.1M | — | — | — | −96.3% |
| Median | 30.0 | 21.2 | 9.7 | +16.7% |